Cargando…

Levorphanol: Revisiting an Underutilized Analgesic

Levorphanol (levo-3-hydroxy-N-methylmorphinan) is a step 3 opioid first developed in the 1940s as an alternative to morphine. Levorphanol belongs to the morphinan opioid series. Levorphanol has greater potency than morphine and is a potent N-methyl-d aspartate (NMDA) antagonist. Levorphanol interfer...

Descripción completa

Detalles Bibliográficos
Autor principal: Prommer, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168847/
https://www.ncbi.nlm.nih.gov/pubmed/25278763
http://dx.doi.org/10.4137/PCRT.S13489
_version_ 1782335629038714880
author Prommer, Eric
author_facet Prommer, Eric
author_sort Prommer, Eric
collection PubMed
description Levorphanol (levo-3-hydroxy-N-methylmorphinan) is a step 3 opioid first developed in the 1940s as an alternative to morphine. Levorphanol belongs to the morphinan opioid series. Levorphanol has greater potency than morphine and is a potent N-methyl-d aspartate (NMDA) antagonist. Levorphanol interferes with the uptake of norepinephrine and serotonin, which makes it potentially useful for neuropathic pain. Glucuronidation changes Levorphanol to Levorphanol-3-glucuronide with excretion by the kidney. Levorphanol has a long half-life and may accumulate with repeated dosing. Levorphanol can be administered orally, intravenously, and subcutaneously. This article provides an update regarding the pharmacodynamics, pharmacology, and clinical efficacy of this often overlooked step 3 opioid.
format Online
Article
Text
id pubmed-4168847
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-41688472014-10-02 Levorphanol: Revisiting an Underutilized Analgesic Prommer, Eric Palliat Care Review Levorphanol (levo-3-hydroxy-N-methylmorphinan) is a step 3 opioid first developed in the 1940s as an alternative to morphine. Levorphanol belongs to the morphinan opioid series. Levorphanol has greater potency than morphine and is a potent N-methyl-d aspartate (NMDA) antagonist. Levorphanol interferes with the uptake of norepinephrine and serotonin, which makes it potentially useful for neuropathic pain. Glucuronidation changes Levorphanol to Levorphanol-3-glucuronide with excretion by the kidney. Levorphanol has a long half-life and may accumulate with repeated dosing. Levorphanol can be administered orally, intravenously, and subcutaneously. This article provides an update regarding the pharmacodynamics, pharmacology, and clinical efficacy of this often overlooked step 3 opioid. Libertas Academica 2014-05-11 /pmc/articles/PMC4168847/ /pubmed/25278763 http://dx.doi.org/10.4137/PCRT.S13489 Text en © 2014 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Review
Prommer, Eric
Levorphanol: Revisiting an Underutilized Analgesic
title Levorphanol: Revisiting an Underutilized Analgesic
title_full Levorphanol: Revisiting an Underutilized Analgesic
title_fullStr Levorphanol: Revisiting an Underutilized Analgesic
title_full_unstemmed Levorphanol: Revisiting an Underutilized Analgesic
title_short Levorphanol: Revisiting an Underutilized Analgesic
title_sort levorphanol: revisiting an underutilized analgesic
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168847/
https://www.ncbi.nlm.nih.gov/pubmed/25278763
http://dx.doi.org/10.4137/PCRT.S13489
work_keys_str_mv AT prommereric levorphanolrevisitinganunderutilizedanalgesic